Meeting Report

Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC


J Adv Pract Oncol 2022;13(6):579-585 | https://doi.org/10.6004/jadpro.2022.13.6.3 | © 2022 Harborside™


  

ABSTRACT

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung cancer, a new drug inhibiting KRAS G12C, and options after disease progression on immune checkpoint inhibitor treatment or targeted treatment.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.